TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25824327

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (anti-VEGF drugs) administered as needed over a 2-year period.
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Eyes with VMT or VMA at baseline
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Eyes without VMT or VMA at baseline
Number of subjects: 1115
Study: 23818591

Group type: EXPERIMENTAL
Intervention: Family-based training program
Number of subjects: 141

Group type: COMPARATOR
Intervention: Head Start alone
Number of subjects: 141

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 141
Study: 21091083

Group type: EXPERIMENTAL
Intervention: FOX (Fitting to Outcomes eXpert) software tool for programming cochlear implant processors
Number of subjects: 8
Study: 20003019

Group type: EXPERIMENTAL
Intervention: Real time adenosine myocardial contrast echocardiography (MCE) using Sonovue and power pulse inversion (ATL 5000) at rest and during adenosine stress
Number of subjects: 76
Study: 17433319

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian fenestration and coagulation (group 1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy (group 2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normal ovaries
Number of subjects: 65
Study: 17144778

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral self help for depression
Number of subjects: 0
Study: 15542165

Group type: EXPERIMENTAL
Intervention: WF10 therapy (0.5 ml/kg body weight, diluted in physiological saline or 5% dextrose water, intravenous infusions over 2 h on 5 consecutive days, every 3 weeks for 2 cycles)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment alone (control group)
Number of subjects: 100
Study: 11103099

Group type: EXPERIMENTAL
Intervention: ipriflavone-containing supplement
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 8956638

Group type: EXPERIMENTAL
Intervention: Gram-positive, coagulase-negative micrococci
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Streptococci
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Enterococci
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Gram-negative organisms
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Positive gram stain or infection with species other than gram-positive, coagulase-negative micrococci
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Initial presenting visual acuity
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Bacterial growth from vitrectomy cassette specimen
Number of subjects: 394
Study: 1550223

Group type: EXPERIMENTAL
Intervention: 0.33 IU/h AVP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.66 IU/h AVP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.99 IU/h AVP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4039118

Group type: EXPERIMENTAL
Intervention: aztreonam-clindamycin
Number of subjects: 80

Group type: COMPARATOR
Intervention: tobramycin-clindamycin
Number of subjects: 80
Study: 31426869

Group type: EXPERIMENTAL
Intervention: Pay-it-forward arm (free gonorrhea and chlamydia testing with donation option)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pay-what-you-want arm (free testing with payment option after receiving the test)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard of care arm (full price for dual gonorrhea and chlamydia testing)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 300
Study: 28841892

Group type: EXPERIMENTAL
Intervention: Price reduction on fruits and vegetables (FV)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Skill-building
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Combined skill-building and price reduction
Number of subjects: 642

Group type: COMPARATOR
Intervention: Control
Number of subjects: 642
Study: 26113281

Group type: EXPERIMENTAL
Intervention: Mineral wristband
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo wristband
Number of subjects: 40

Group type: COMPARATOR
Intervention: No wristband
Number of subjects: 40
Study: 23803591

Group type: EXPERIMENTAL
Intervention: Bisoprolol/hydrochlorothiazide 5/6.25 mg (n=89; R)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Amlodipine/valsartan 5/160 mg (n=94; E)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Comparison of R vs E
Number of subjects: 183
Study: 21561347

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 342

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 342
Study: 19572934

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) regional caffeine at 10 mg/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Systemic caffeine at 10 mg/kg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16511940

Group type: EXPERIMENTAL
Intervention: Reciprocating syringe
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 32
Study: 15497669

Group type: COMPARATOR
Intervention: 50 mg losartan tablets (Sarvas)
Number of subjects: 24

Group type: COMPARATOR
Intervention: losartan/hydrochlorothiazide (50 mg/12.5 mg) (Sarvastan)
Number of subjects: 24

Group type: COMPARATOR
Intervention: E3174 (metabolite of losartan)
Number of subjects: 24

Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 24
Study: 11673925

Group type: EXPERIMENTAL
Intervention: Suction drainage (n=45)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No suction drainage (n=32)
Number of subjects: 77
Study: 9624069

Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 438
Study: 8164026

Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied to half of the back for 6 months
Number of subjects: 5

Group type: COMPARATOR
Intervention: Untreated nevi
Number of subjects: 5
Study: 2452563

Group type: EXPERIMENTAL
Intervention: Group A: 20 mg rscu-PA bolus followed by 60 mg infusion over 1 hour
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group B: 10 mg rscu-PA bolus followed by 30 mg infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 80 mg rscu-PA
Number of subjects: 24
Study: 29739454

Group type: EXPERIMENTAL
Intervention: 1.5% L-menthol application
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no menthol application)
Number of subjects: 17
Study: 25288372

Group type: EXPERIMENTAL
Intervention: Cervical vestibular evoked myogenic potential (cVEMP) responses in severe OSAS patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cervical vestibular evoked myogenic potential (cVEMP) responses in control group (snoring without OSAS, AHI <5)
Number of subjects: 54
Study: 23942181

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cell transplantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 21600759

Group type: EXPERIMENTAL
Intervention: Temozolomide (150 mg/m²/day for 7 days every 2 weeks)
Number of subjects: 859

Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m²/day on day 1 every 3 weeks)
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 859

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 859
Study: 17875806

Group type: EXPERIMENTAL
Intervention: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide (100 mg per day during 6 months) (arm B)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Tandem autologous stem-cell transplantation (arm A)
Number of subjects: 195
Study: 16421420

Group type: EXPERIMENTAL
Intervention: Temozolomide (150 mg/m2 for 7 days every other week) and Thalidomide (50 to 400 mg daily)
Number of subjects: 29
Study: 15050984

Group type: EXPERIMENTAL
Intervention: Advance EC
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control
Number of subjects: 301
Study: 10996232

Group type: EXPERIMENTAL
Intervention: Tympanometry (TYMP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acoustic Reflectometry (AR)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined test (TYMP and AR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal ears (control group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Ears with effusion (control group)
Number of subjects: 31
Study: 9167375

Group type: EXPERIMENTAL
Intervention: Plasma serotonin levels in patients with acute appendicitis
Number of subjects: 95

Group type: COMPARATOR
Intervention: Plasma serotonin levels in patients with abdominal pain of other etiologies
Number of subjects: 95

Group type: COMPARATOR
Intervention: Plasma serotonin levels in healthy controls
Number of subjects: 95
Study: 1362556

Group type: EXPERIMENTAL
Intervention: Suriclone 0.4 mg tid (young)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (young and elderly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suriclone 0.1 mg and 0.2 mg tid (elderly)
Number of subjects: 0
Study: 3104448

Group type: EXPERIMENTAL
Intervention: Camcolit‐400
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priadel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New micro‐encapsulated formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liskonum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Litarex
Number of subjects: 0

Group type: COMPARATOR
Intervention: All 5 preparations
Number of subjects: 0
Study: 28585182

Group type: EXPERIMENTAL
Intervention: Lime powder (LP) treatment for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27270470

Group type: EXPERIMENTAL
Intervention: High-speed power training for knee extensors (12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 23604058

Group type: EXPERIMENTAL
Intervention: Sternotomy
Number of subjects: 111

Group type: COMPARATOR
Intervention: Pericardial drainage and wash-out
Number of subjects: 111
Study: 23121440

Group type: EXPERIMENTAL
Intervention: Natural grass
Number of subjects: 13

Group type: COMPARATOR
Intervention: Artificial turf
Number of subjects: 13
Study: 20131302

Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 84
Study: 18427313

Group type: EXPERIMENTAL
Intervention: Full-endoscopic posterior foraminotomy
Number of subjects: 175

Group type: COMPARATOR
Intervention: Conventional microsurgical anterior cervical discectomy
Number of subjects: 175
Study: 16365061

Group type: EXPERIMENTAL
Intervention: 20 g FOS
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12860366

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observation-only control group
Number of subjects: 67
Study: 11299572

Group type: EXPERIMENTAL
Intervention: Larval debridement therapy (LDT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydrogel dressings (control)
Number of subjects: 12
Study: 9058684

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.56 mg per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.28 mg per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: On-demand azelastine use
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8364018

Group type: EXPERIMENTAL
Intervention: Indobufen 50 mg BID
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg BID
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg BID
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 9
Study: 3539127

Group type: EXPERIMENTAL
Intervention: lonazolac 300 mg b.i.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: indomethacin 75 mg b.i.d.
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 29952839

Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham intervention (0 mm Hg)
Number of subjects: 10
Study: 28965068

Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 203
Study: 25917060

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 24749843

Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical fluorouracil cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAL-PDT
Number of subjects: 0
Study: 23355301

Group type: EXPERIMENTAL
Intervention: Rolofylline (1 to 60 mg, infused over 1-2 hours)
Number of subjects: 36
Study: 20149236

Group type: EXPERIMENTAL
Intervention: ESCAPE-knee pain rehabilitation programme
Number of subjects: 29
Study: 19026238

Group type: EXPERIMENTAL
Intervention: Simulated road environment training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16901888

Group type: EXPERIMENTAL
Intervention: Brief, tailored physical activity intervention with a booster phone call 2 weeks later
Number of subjects: 287
Study: 12789232

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (2-week course)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Moderate-to-severe asthma
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 25

Group type: COMPARATOR
Intervention: All asthma groups
Number of subjects: 25
Study: 12498543

Group type: COMPARATOR
Intervention: 90‐min resting preoxygenation control
Number of subjects: 60

Group type: COMPARATOR
Intervention: 240‐min resting preoxygenation control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 90‐min preoxygenation including exercise during the first 15 min
Number of subjects: 60
Study: 10523461

Group type: EXPERIMENTAL
Intervention: Glycemia control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Particular therapy
Number of subjects: 0
Study: 8821611

Group type: COMPARATOR
Intervention: Triple therapy (tripotassium dicitrato bismuthate 120 mg qds+tetracycline 500 mg qds+metronidazole 400 mg qds)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quadruple therapy A (triple therapy+omeprazole 20 mg od)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quadruple therapy B (triple therapy+omeprazole 40 mg od)
Number of subjects: 60
Study: 2031678

Group type: EXPERIMENTAL
Intervention: Polyurethane film (Opsite)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Impregnated gauze (Jelonet)
Number of subjects: 55
Study: 7152081

Group type: EXPERIMENTAL
Intervention: 0.05% diflorasone diacetate ointment applied once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Betamethasone valerate ointment applied twice daily
Number of subjects: 60
Study: 3932648

Group type: EXPERIMENTAL
Intervention: 2/0 polypropylene (Prolene) suture
Number of subjects: 111

Group type: COMPARATOR
Intervention: Polydioxanone (PDS) suture
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both interventions (Prolene and PDS)
Number of subjects: 111
Study: 31977825

Group type: EXPERIMENTAL
Intervention: Reverse total shoulder arthroplasty (TSA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reverse TSA for type-C2 fractures
Number of subjects: 124

Group type: COMPARATOR
Intervention: ORIF for type-C2 fractures
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Reverse TSA for type-B2 fractures
Number of subjects: 124

Group type: COMPARATOR
Intervention: ORIF for type-B2 fractures
Number of subjects: 124
Study: 29189662

Group type: EXPERIMENTAL
Intervention: Modified group with suction drains (remained in place until 12 hours after surgery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard group (no suction drains)
Number of subjects: 120
Study: 26026604

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) treatment
Number of subjects: 78
Study: 25682570

Group type: EXPERIMENTAL
Intervention: Indoor bicycle exercise program for twelve weeks
Number of subjects: 33
Study: 24338461

Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intraarticular steroid injection
Number of subjects: 120
Study: 20538138

Group type: EXPERIMENTAL
Intervention: Highest quartile of Lp(a) distribution (>/=32.9 mg/dl)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Lowest quartile of Lp(a) distribution (<32.9 mg/dl)
Number of subjects: 1002
Study: 18261061

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Headbox oxygen
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 93
Study: 16368299

Group type: EXPERIMENTAL
Intervention: Tomato extract, 250 mg Lyc-O-Mato, during an 8-week treatment period
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo during the 4-week placebo period
Number of subjects: 31
Study: 15018673

Group type: EXPERIMENTAL
Intervention: Priming personal self-standards in Experiment I
Number of subjects: 2

Group type: COMPARATOR
Intervention: Priming no standards or normative self-standards in Experiment I
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Priming personal self-standards in Experiment II
Number of subjects: 2
Study: 10893359

Group type: EXPERIMENTAL
Intervention: Added dead space during exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control exercise (without added dead space)
Number of subjects: 7
Study: 9368236

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (200 mg/day for 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment without magnesium supplementation (control group)
Number of subjects: 50
Study: 1544017

Group type: EXPERIMENTAL
Intervention: One dose of antidepressant medication at night
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Three doses of medication during the day
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Patient-chosen regime (either A or B)
Number of subjects: 89

Group type: COMPARATOR
Intervention: All regimes (once-a-day and three-times-a-day)
Number of subjects: 89
Study: 3929553

Group type: EXPERIMENTAL
Intervention: High dose fentanyl (50 micrograms/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 32
Study: 31790604

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30326883

Group type: EXPERIMENTAL
Intervention: iMOVE therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 42
Study: 27721227

Group type: EXPERIMENTAL
Intervention: Nasal oxygen supplementation (2 L/min to 3 L/min) with standard hydration (n = 176)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard hydration alone (control group) (n = 176)
Number of subjects: 348
Study: 25467955

Group type: EXPERIMENTAL
Intervention: Wedged insole intervention to reduce peak external knee adduction moments (KAMs)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist control group with no intervention
Number of subjects: 46
Study: 22849536

Group type: EXPERIMENTAL
Intervention: Sweet orange essential oil (2.5 drops)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sweet orange essential oil (10 drops)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tea tree essential oil (control aroma: 2.5 drops)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water (nonaromatic control: 2.5 drops)
Number of subjects: 40
Study: 20105676

Group type: EXPERIMENTAL
Intervention: Vinyl Polysiloxane (VPS) with full-arch tray
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polyether (PE) with full-arch tray
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vinyl Polysiloxane (VPS) with dual-arch tray
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polyether (PE) with dual-arch tray
Number of subjects: 50
Study: 18325675

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) as an adjunct to analgesia and sedation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Basic cognitive therapy (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR)
Number of subjects: 42
Study: 16146625

Group type: EXPERIMENTAL
Intervention: Genesis Total Knee Arthroplasty System (cemented components)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Genesis Total Knee Arthroplasty System (cementless components)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Genesis Total Knee Arthroplasty System
Number of subjects: 74
Study: 12925455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943

Group type: COMPARATOR
Intervention: Pexelizumab 2.0 mg/kg bolus
Number of subjects: 943

Group type: COMPARATOR
Intervention: Pexelizumab 2.0 mg/kg bolus plus 0.05 mg/kg per h for 20 hours
Number of subjects: 943
Study: 10800064

Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporin A) at twice the last i.v. dose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neoral (cyclosporin A) at the same last i.v. dose
Number of subjects: 14
Study: 8717398

Group type: EXPERIMENTAL
Intervention: Hybrid vaccine combining outer membrane protein F (OprF) and outer membrane protein I (OprI)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral immunization with recombinant OprI expressing Salmonella dublin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Recombinant OprI immunization in human volunteers
Number of subjects: 90
Study: 1449918

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg three times daily for 28 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 20 mg three times daily for 28 days
Number of subjects: 105
Study: 6727272

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 20 mg diltiazem hydrochloride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of 120 mg diltiazem in solution form
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral administration of 120 mg diltiazem as two 60-mg sustained-release tablets
Number of subjects: 6
Study: 29248897

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 2149
Study: 28283202

Group type: EXPERIMENTAL
Intervention: Educational course on VAP prevention guidelines
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 105